Lab supply 99% pure Ace-083 Peptides powder 


ACE-083 1MG

ACE-083 is an investigational protein therapeutic that has been designed for local administration to increase muscle mass and strength in specific muscles and muscle groups.  Acceleron is developing ACE-083 for diseases in which improved muscle strength may provide a clinical benefit, such as inclusion body myositis and certain forms of muscular dystrophy.
Select proteins in the TGF-β protein superfamily normally function to modulate muscle growth. ACE-083 has been designed to block those proteins and, in doing so, can increase muscle mass and strength.  ACE-083 has been engineered to exert this action only within the muscle or muscle group treated. In preclinical animal studies, ACE-083 has shown selective and dose-dependent increases in muscle mass in treated muscles with no effects in untreated muscles.


A trial about ACE-083
Background: ACE-083 is an investigational protein therapeutic that acts as a localized ligand trap for myostatin (GDF8) and other negative regulators of muscle growth in the TGF-β superfamily. In wild-type mice and the mdxmodel of Duchenne muscular dystrophy (DMD), local injection of ACE-083 into a target muscle led to dose-dependent increases in muscle mass and force with no systemic pharmacodynamic (PD) effects.


Methods: This is a single-center double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and PD effects of ACE-083 in healthy, postmenopausal women. Five cohorts of 8 subjects each were randomized to ACE-083 (n=6) or placebo (n=2), administered as 2-4 EMG-guided injections into the right rectus femoris (RF) muscle: Cohorts 1-3 (50, 100, 200 mg) on Day 1, and Cohorts 4-5 (100, 200 mg) on Days 1 and 22. MRI to assess thigh muscle volume was performed at baseline, and 3 and 8 weeks after last dose. Fixed and hand-held knee extension strength measurements were evaluated during treatment and follow-up. Additional cohorts to evaluate injections into the tibialis anterior muscle and dorsiflexion are ongoing.


Results: The difference in mean % change in RF muscle volume from baseline between the injected right RF and the uninjected left RF at 3 weeks after the last dose was +0.6% in the placebo group, compared to +1.2%, +2.8%, +4.2%, +6.2%, and +13.2% in ACE-083-treated subjects from cohorts 1-5, respectively. In Cohorts 2-5, RFmuscle volume remained increased, though attenuated, at 8 weeks after the last dose. Changes in knee extension strength did not correlate with muscle volume increases in these healthy subjects. All AEs were grade 1-2 and reversible. The most frequent related AEs (≥15%) included injection site pain, muscle twitching, myalgia, and injection site reaction, with similar incidences in active- and placebo-treated groups.
Conclusions: Local administration of ACE-083 into the RF muscle was well-tolerated and associated with dose-dependent increases in RF muscle volume. These observed increases in muscle mass compare favorably with systemic agents in development and support further studies of ACE-083 in diseases with focal muscle involvement, such as facioscapulohumeral muscular dystrophy (FSHD).
- See more at: http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2016.GF-TK-GPCR-ISB.4.LBSAT-07#sthash.ATUO9jrU.dpuf




Hot selling item:

Lab supply 99% pure Ace-083 Peptides powder 


ACE-083 1MG

ACE-083 is an investigational protein therapeutic that has been designed for local administration to increase muscle mass and strength in specific muscles and muscle groups.  Acceleron is developing ACE-083 for diseases in which improved muscle strength may provide a clinical benefit, such as inclusion body myositis and certain forms of muscular dystrophy.
Select proteins in the TGF-β protein superfamily normally function to modulate muscle growth. ACE-083 has been designed to block those proteins and, in doing so, can increase muscle mass and strength.  ACE-083 has been engineered to exert this action only within the muscle or muscle group treated. In preclinical animal studies, ACE-083 has shown selective and dose-dependent increases in muscle mass in treated muscles with no effects in untreated muscles.


A trial about ACE-083
Background: ACE-083 is an investigational protein therapeutic that acts as a localized ligand trap for myostatin (GDF8) and other negative regulators of muscle growth in the TGF-β superfamily. In wild-type mice and the mdxmodel of Duchenne muscular dystrophy (DMD), local injection of ACE-083 into a target muscle led to dose-dependent increases in muscle mass and force with no systemic pharmacodynamic (PD) effects.


Methods: This is a single-center double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and PD effects of ACE-083 in healthy, postmenopausal women. Five cohorts of 8 subjects each were randomized to ACE-083 (n=6) or placebo (n=2), administered as 2-4 EMG-guided injections into the right rectus femoris (RF) muscle: Cohorts 1-3 (50, 100, 200 mg) on Day 1, and Cohorts 4-5 (100, 200 mg) on Days 1 and 22. MRI to assess thigh muscle volume was performed at baseline, and 3 and 8 weeks after last dose. Fixed and hand-held knee extension strength measurements were evaluated during treatment and follow-up. Additional cohorts to evaluate injections into the tibialis anterior muscle and dorsiflexion are ongoing.


Results: The difference in mean % change in RF muscle volume from baseline between the injected right RF and the uninjected left RF at 3 weeks after the last dose was +0.6% in the placebo group, compared to +1.2%, +2.8%, +4.2%, +6.2%, and +13.2% in ACE-083-treated subjects from cohorts 1-5, respectively. In Cohorts 2-5, RFmuscle volume remained increased, though attenuated, at 8 weeks after the last dose. Changes in knee extension strength did not correlate with muscle volume increases in these healthy subjects. All AEs were grade 1-2 and reversible. The most frequent related AEs (≥15%) included injection site pain, muscle twitching, myalgia, and injection site reaction, with similar incidences in active- and placebo-treated groups.
Conclusions: Local administration of ACE-083 into the RF muscle was well-tolerated and associated with dose-dependent increases in RF muscle volume. These observed increases in muscle mass compare favorably with systemic agents in development and support further studies of ACE-083 in diseases with focal muscle involvement, such as facioscapulohumeral muscular dystrophy (FSHD).
- See more at: http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2016.GF-TK-GPCR-ISB.4.LBSAT-07#sthash.ATUO9jrU.dpuf




Hot selling item:

Homecare Devices

Home Care Devices,Household Standby Medical Devices,Home Medical Equipment,Home Medical Services

Surgimed Medical Supplies Co.,Ltd , https://www.surgimedcn.com